Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures
News May 03, 2013
Zytoprotec has announced that it has raised EUR 2 million in financing from new investor Baxter Ventures towards a EUR 4 million Series A financing.
Baxter Ventures is an investment initiative established by Baxter International in 2011 to invest up to USD 200 million in promising companies.
As a result of the financing Norbert Riedel, Ph.D., Baxter’s Chief Science and Innovation Officer will join Zytoprotec’s Supervisory Board.
Zytoprotec’s most advanced product, PD-protec™, is a next-generation solution for peritoneal dialysis (PD) designed to actively protect abdominal cells.
The peptide used as the cytoprotective component of PD-protec™ is patent-protected by Zytoprotec. The product has completed a Phase I/II trial in 2012 and a Phase II trial is planned to commence in early 2013.
“We are very pleased to add Baxter to our investor base, given the company’s longstanding expertise and leadership in PD therapy”, Peter C. Weilguni, Chief Executive Officer of Zytoprotec, commented.
Weilguni continued, “We welcome Dr. Riedel to the Board of our Company as we are preparing PD-protec™ for a Phase II clinical trial.”
“Zytoprotec offers an exciting technology opportunity to protect the peritoneal membrane”, commented Norbert Riedel, Ph.D, Baxter’s Chief Science and Innovation Officer.
Riedel continued, “A peritoneal dialysis solution that holds the potential to prolong treatment time on PD would bring significant benefits to patients with kidney disease.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018